Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Moderna Meet Its COVID Vaccine Expectations?

Non-Profit Competition Will Hit Revenues

Executive Summary

Analysts have cut forecasts for Moderna’s COVID-19 vaccine – but there is still much to play for as key readouts approach.

You may also be interested in...



Moderna Increases Minimum Supply Of Coronavirus Vaccine Doses For 2021

The company’s announcement that it would supply at least 600 million doses of mRNA-1273 came as US vaccination rates have fallen far short of expectations.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector. 

Coronavirus Update: Inside Moderna's Deal With The US

Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel